Literature DB >> 30185470

Perspective: Will We Ever Know the Optimal Hgb Level in ESRD?

Jay B Wish1.   

Abstract

Entities:  

Keywords:  ESRD; anemia; erythropoietin; hemoglobin

Mesh：

Substances：

Year:  2018        PMID： 30185470      PMCID： PMC6171266          DOI： 10.1681/ASN.2018040363

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  9 in total

1.  Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.

Authors:  Glenn M Chertow; Jiannong Liu; Keri L Monda; David T Gilbertson; M Alan Brookhart; Anne C Beaubrun; Wolfgang C Winkelmayer; Allan Pollock; Charles A Herzog; Akhtar Ashfaq; Til Sturmer; Kenneth J Rothman; Brian D Bradbury; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2016-02-25       Impact factor: 10.121

2.  NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative.

Authors: 
Journal:  Am J Kidney Dis       Date:  1997-10       Impact factor: 8.860

3.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

4.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Authors:  A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

5.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

6.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Authors:  Lynda A Szczech; Huiman X Barnhart; Jula K Inrig; Donal N Reddan; Shelly Sapp; Robert M Califf; Uptal D Patel; Ajay K Singh
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

Review 7.  Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.

Authors:  Nupur Gupta; Jay B Wish
Journal:  Am J Kidney Dis       Date:  2017-02-24       Impact factor: 8.860

8.  Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.

Authors:  Cunlin Wang; Robert Kane; Mark Levenson; Jeffrey Kelman; Michael Wernecke; Joo-Yeon Lee; Steven Kozlowski; Carmen Dekmezian; Zhiwei Zhang; Aliza Thompson; Kimberly Smith; Yu-Te Wu; Yuqin Wei; Yoganand Chillarige; Qin Ryan; Chris Worrall; Thomas E MaCurdy; David J Graham
Journal:  JAMA Intern Med       Date:  2016-12-01       Impact factor: 21.873

9.  The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.

Authors:  Daniel W Coyne
Journal:  Kidney Int       Date:  2012-03-21       Impact factor: 10.612
  9 in total
  1 in total

1.  Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada.

Authors:  Mark Canney; Peter Birks; Selena Shao; Patrick Parfrey; Ognjenka Djurdjev; Adeera Levin
Journal:  Kidney Int Rep       Date:  2021-01-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.